课题基金 / 基金详情

Cyclin-Dependent Kinase Inhibitor suppresses the growth in oral squamous cell carcinoma cells

Cyclin-Dependent Kinase Inhibitor suppresses the growth in oral squamous cell carcinoma cells
细胞周期蛋白依赖性激酶抑制剂抑制口腔鳞状细胞癌细胞的生长
批准号:
12671938
负责人:
SHINTANI Satoru
金额:
$2.18万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2001

项目摘要

项目成果

SHINTANI Satoru的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Cyclin-dependent kinases (CDKs) play an essential role in intracellular control of cell cycle. CDK inhinitors (Flavopiridol and Roscpvitine) that inhibits tumor growth in vitro and in vivo by because of the inhibiting CDKs. These agents are known to inhibit CDK2, CDK4 and CDK7 activities, to diminish cyclin Dl expressions, and to induce apoptosis. However, effects of CDK inhibitors against oral squamous cell carcinoma (OSCC) cells and mechanisms of these agents mediated cytotoxicity have not been fully elucidated.In this study, we have investigated effects of CDK inhibitors in OSCC cell lines and studied mechanisms of CDK inhibitors mediated-apoptosis. CDK inhibitors were found to inhibit the growth of all five OSCC cells in time and dose-dependent manner and to diminish CDKs activities. Induction of apoptosis was observed in all cells, as well as cells with sub-Gl DNA contents, DNA fragmentations, and PARP cleavages. No alternation of expression levels of Bcl-2, an apoptosis regulator was observed. In contrast, Bcl-XL was down regulated and Bcl-Xs was up regulated after being exposed to CDK inhibitors. CDK inhibitors treatments also resulted in remarkable reductions of cyclin A, cyclin B, and cyclin Dl expressions in OSCC cells. We also found that expression levels of CDK Activation Kinase and CDC25C were reduced, and p34 CDK2 that phosphorylated in Thr 14 and Tyr 15: inactive form were up-regulated after CDK inhibitors exposure.Our data indicate that CDK inhibitors has growth inhibition activities against OSCC in vitro. CDK inhibitors not only inhibits CDKs directly, but it also inhibits CDKs activation pathway and activates Bcl-X apoptotic pathway.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
S. Shintani, M. Mihara, Y. Nakahara, A. Kiyota, Y. Ueyama, T. Matsumura, D. Wong: "Expression of Cell Cycle Control Proteins in Normal Epithelium, Premalignant and Malignant Lesions of Oral Cavity"Oral Oncology. (in press). (2002)
S. Shintani、M. Mihara、Y. Nakahara、A. Kiyota、Y. Ueyama、T. Matsumura、D. Wong:“细胞周期控制蛋白在正常上皮、口腔癌前和恶性病变中的表达”口腔肿瘤学。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
M.Mihara, S.Shintani, Y.Nakahara, A.Kiyota, Y.Ueyama, T.Matsumura, D.Wong: "Overexpression of CDK2 is a Prognostic Indicator of Oral Cancer Progression"Japanese Journal of Cancer Research. 92. 352-360 (2001)
M.Mihara、S.Shintani、Y.Nakahara、A.Kiyota、Y.Ueyama、T.Matsumura、D.Wong:“CDK2 的过度表达是口腔癌进展的预后指标”日本癌症研究杂志。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
M.Mihara, S.Shintani, Y.Nakahara, A.Kiyota, Y.Ueyama T Matsumura, D.Wong: "Overexpression of CDK2 is a Prognostic Indicator of Oral Cancer Progression"Japanese Journal of Cancer Research. 92. 352-360 (2001)
M.Mihara、S.Shintani、Y.Nakahara、A.Kiyota、Y.Ueyama T Matsumura、D.Wong:“CDK2 的过度表达是口腔癌进展的预后指标”日本癌症研究杂志。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
The regenerative therapy of the jaw by auto-transplantation of adipose-derived stem cells
  • 批准号:
    23659956
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
  • 资助金额:
    $2.25万
  • 财政年份:
    2011
  • 负责人:
    SHINTANI Satoru
  • 依托单位:
Telomerase-Specific Replication-Selective Virotherapy for oral squamous cell carcinoma cell lines
  • 批准号:
    20390520
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
  • 资助金额:
    $12.48万
  • 财政年份:
    2008
  • 负责人:
    SHINTANI Satoru
  • 依托单位:
Basic research for Molecular target therapy on Oral Cancer
  • 批准号:
    14370675
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
  • 资助金额:
    $9.15万
  • 财政年份:
    2002
  • 负责人:
    SHINTANI Satoru
  • 依托单位:
海外基金